Bylund James
Known title: Chief Operating OfficerCIK: 0001849642
Associated companies
Transaction History
| RGEN | ▲ Buy | Grant | 7,751 | $0 | 3/5/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 125 | $0 | 3/4/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 62 | $8K | 3/4/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 2,433 | $304K | 3/2/2026 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 1,478 | $190K | 2/27/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 2,191 | $331K | 11/18/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 454 | $58K | 4/1/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 381 | $0 | 3/13/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 175 | $25K | 3/13/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 6,435 | $0 | 3/3/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 1,239 | $193K | 3/3/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 1,285 | $201K | 2/27/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 543 | $89K | 2/24/2025 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 444 | $81K | 4/2/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 1,206 | $236K | 3/7/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 22 | $4K | 3/5/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 197 | $38K | 3/4/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 50 | $0 | 3/1/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 820 | $157K | 3/1/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 404 | $0 | 2/29/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 8,691 | $0 | 2/27/2024 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 940 | $89K | 2/23/2024 | View on chart |
| RGEN | ▼ Sell | Open Market | 4,373 | $866K | 2/23/2024 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 334 | $55K | 4/4/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 625 | $0 | 3/3/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 210 | $39K | 3/3/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 8,348 | $0 | 3/2/2023 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 594 | $103K | 2/28/2023 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 2,000 | $189K | 8/3/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 2,000 | $481K | 8/3/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 335 | $63K | 4/1/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 3,366 | $0 | 2/24/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 188 | $36K | 2/24/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 900 | $0 | 2/17/2022 | View on chart |
| RGEN | ▼ Sell | Tax Withholding | 334 | $61K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.